Cancer Cause and Prevention Research in Massachusetts
Cancer Cause and Prevention Research (93.393) awarded $351 million to recipients in Massachusetts in 220 grants from fiscal 2021 to 2025, 9.7% of the program's national total. Dana-Farber Cancer Institute, Inc. received the most, $83.1 million.
- Awarded in Massachusetts$351 million
- Awards220
- Share of the program9.7%
- Rank among states3rd of 48
- National total$3.6 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 105 | $60.3 million |
| FY 2022 | 117 | $65.1 million |
| FY 2023 | 109 | $64.1 million |
| FY 2024 | 120 | $73.9 million |
| FY 2025 | 113 | $87.2 million |
Recipients in Massachusetts
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| Dana-Farber Cancer Institute, Inc. | Nonprofits | 51 | $83.1 million |
| The General Hospital Corporation | Nonprofits | 40 | $57.1 million |
| President and Fellows of Harvard College | Colleges and universities | 16 | $51.5 million |
| Brigham & Womens Hospital Inc | Nonprofits | 26 | $42.7 million |
| Trustees of Boston University | Colleges and universities | 10 | $21.1 million |
| University of Massachusetts Medical School | Colleges and universities | 12 | $15.3 million |
| President and Fellows of Harvard College | Colleges and universities | 8 | $14.4 million |
| The Children's Hospital Corporation | Nonprofits | 6 | $10.4 million |
| Tufts Medical Center Parent, Inc. | Nonprofits | 4 | $10.4 million |
| Beth Israel Deaconess Medical Center, Inc. | Nonprofits | 9 | $9.3 million |
Open opportunities under this program
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
- Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
See all 60 on the program page
Questions people ask
How much Cancer Cause and Prevention Research money goes to Massachusetts?
$351 million from fiscal 2021 to 2025, across 220 awards. Massachusetts ranks 3rd of 48 states and territories for this program.
Who receives Cancer Cause and Prevention Research money in Massachusetts?
The largest recipient is Dana-Farber Cancer Institute, Inc., with $83.1 million in 51 awards. Next are The General Hospital Corporation and President and Fellows of Harvard College.
Can organizations in Massachusetts apply now?
Yes, 60 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
Cancer Cause and Prevention Research in other states
Other large programs in Massachusetts
- Grants to States for Medicaid
- Highway Planning and Construction
- Education Stabilization Fund
- Children's Health Insurance Program
- Disaster Grants - Public Assistance (Presidentially Declared Disasters)
- Temporary Assistance for Needy Families
- Federal Transit Formula Grants
- National School Lunch Program
- Allergy and Infectious Diseases Research
- Aging Research